UBS initiated coverage of Kaken Pharmaceutical (KKPCF) with a Neutral rating and 4,200 yen price target he firm says the company’s business stability is priced into the shares with limited catalysts ahead.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential